Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Suspended 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 77Myelodysplastic Syndromes 20Leukemia, Myelomonocytic, Chronic 11Myeloproliferative Disorders 6Hematologic Neoplasms 5Anemia, Refractory, with Excess of Blasts 4Recurrence 3Neoplasms 3Myelodysplastic-Myeloproliferative Diseases 3Leukemia 3Hematologic Diseases 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2GATA2 Deficiency 2Sarcoma, Myeloid 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pathologic Complete Response 1Neurofibromatosis 1 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1

Interventions

Gemcitabine 3Cyclophosphamide 3romidepsin 2pembrolizumab 2duvelisib 2Vincristine 2Prednisone 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Biopsy 2Azacitidine 2tazemetostat 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1ruxolitinib 1ixazomib 1ivarmacitinib 1fludarabine 1etoposide phosphate 1cemiplimab 1cabiralizumab 1belinostat 1X-Rays 1Watchful Waiting 1Tomography, X-Ray Computed 1Specimen Handling 1Salvage Therapy 1Prednisolone 1Photons 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × Azacitidine × 90 days × Clear all
NCT07388563 2026-05-08

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Suspended
20 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05182957 2026-05-01

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

The First Affiliated Hospital of Soochow University

Phase 2 Recruiting
31 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡